The unknown biology of the unknown primary tumour: a literature review.

The unknown primary tumour (UPT) is an intriguing clinical phenomenon found in approximately 5% of all newly diagnosed patients with cancer. It is unclear whether UPT forms a distinct biological entity with specific genetic and phenotypic characteristics, or whether it is merely a clinical presentation of metastases in patients in whom the primary tumour cannot be detected and does not result in any visible clinical signs. Understanding the basic biology of UPT may shed light on this issue and, moreover, may have a direct impact on clinical care. A review of the literature revealed only a limited number of publications describing the genetic and phenotypic features of UPT, most of which focus only on the potential of these markers to predict prognosis. The question as to whether the biology of UPT is different from tumours of known primaries therefore remains unanswered. Further insight into the molecular mechanisms underlying the oncogenesis of UPT, e.g. by applying newly available DNA and gene profiling microarray techniques, will be necessary to understand its specific biology and to develop more effective treatments.

[1]  Manuel Molina,et al.  Unknown primary , 2004, Journal of surgical oncology.

[2]  C. la Vecchia,et al.  Epidemiology of unknown primary tumours. , 2002, European journal of cancer.

[3]  J. Hainsworth,et al.  Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Coebergh,et al.  Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. , 2002, European journal of cancer.

[5]  F. Kokocinski,et al.  Automated Screening for Genomic Imbalances using Matrix-Based Comparative Genomic Hybridization , 2002, Laboratory Investigation.

[6]  P. Jallepalli,et al.  Chromosome segregation and cancer: cutting through the mystery , 2001, Nature Reviews Cancer.

[7]  C. Klein,et al.  Early cancer cell dissemination and late metastatic relapse: clinical reflections and biological approaches to the dormancy problem in patients. , 2001, Seminars in cancer biology.

[8]  J. Hainsworth,et al.  Taxane-based chemotherapy for patients with carcinoma of unknown primary site. , 2001, Cancer journal.

[9]  J. Hainsworth,et al.  Gemcitabine in the Second-Line Therapy of Patients with Carcinoma of Unknown Primary Site: A Phase II Trial of the Minnie Pearl Cancer Research Network , 2001, Cancer investigation.

[10]  B. Trock,et al.  C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance , 2000, British Journal of Cancer.

[11]  James D. Evans,et al.  K‐ras oncogene subtype mutations are associated with survival but not expression of p53, p16INK4A, p21WAF‐1, cyclin D1, erbB‐2 and erbB‐3 in resected pancreatic ductal adenocarcinoma , 2000, International journal of cancer.

[12]  C. Rinker-Schaeffer,et al.  Metastasis-suppressor genes: a review and perspective on an emerging field. , 2000, Journal of the National Cancer Institute.

[13]  Karen H. Vousden,et al.  The ins and outs of p53 , 2000, Nature Cell Biology.

[14]  J. Hainsworth,et al.  Management of patients with cancer of unknown primary site. , 2000, Oncology.

[15]  T. Liehr,et al.  Patterns of genomic imbalances in human solid tumors (Review). , 2000, International journal of oncology.

[16]  J. Hainsworth,et al.  Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  J. Hainsworth,et al.  Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Friberg,et al.  18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). , 1999, European journal of cancer.

[19]  J. Arends,et al.  Relevance of the expression of bcl-2 in combination with p53 as a prognostic factor in breast cancer. , 1998, Anticancer research.

[20]  A. Horwich,et al.  Establishing Germ Cell Origin of Undifferentiated Tumors by Identifying Gain of 12p Material Using Comparative Genomic Hybridization Analysis of Paraffin‐Embedded Samples , 1998, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[21]  W. Kuo,et al.  High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays , 1998, Nature Genetics.

[22]  S. Knuutila,et al.  DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. , 1998, The American journal of pathology.

[23]  N. Pavlidis,et al.  Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study. , 1998, Anticancer research.

[24]  J. Roodenburg,et al.  Detection of unknown occult primary tumors using positron emission tomography , 1998, Cancer.

[25]  Y. Nishiwaki,et al.  Role of epidermal growth factor receptor overexpression, K-ras point mutation and c-myc amplification in the carcinogenesis of non-small cell lung cancer. , 1998, Oncology reports.

[26]  T. Shankey,et al.  Common patterns of genetic evolution in human solid tumors. , 1997, Cytometry.

[27]  B Johansson,et al.  Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. , 1997, Cancer research.

[28]  J. Hainsworth,et al.  Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Arends,et al.  Microvessel density in unknown primary tumors , 1997, International journal of cancer.

[30]  C. Croce,et al.  Bcl2 is the guardian of microtubule integrity. , 1997, Cancer research.

[31]  S. Fox,et al.  Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. , 1996, European journal of cancer.

[32]  B. Iacopetta,et al.  Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. , 1996, Human pathology.

[33]  A. Harris,et al.  EARLY EXPRESSION OF bcl‐2 PROTEIN IN THE ADENOMA–CARCINOMA SEQUENCE OF COLORECTAL NEOPLASIA , 1996, The Journal of pathology.

[34]  A. Sandberg,et al.  Reviews of chromosome studies in urological tumors. III. Cytogenetics and genes in testicular tumors. , 1996, The Journal of urology.

[35]  B. Lembersky,et al.  Metastases of unknown primary site. , 1996, The Medical clinics of North America.

[36]  N. Pavlidis,et al.  Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. , 1995, Anticancer research.

[37]  K. Bland,et al.  Oncogene Protein Co‐Expression Value of Ha-ras, c-myc, c-fos, and p53 as Prognostic Discriminants for Breast Carcinoma , 1995, Annals of surgery.

[38]  R. Motzer,et al.  Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  K. Hess,et al.  Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  G. Daugaard Unknown primary tumours. , 1994, Cancer treatment reviews.

[41]  H. Kim,et al.  Expression of cellular oncogenes in human gastric carcinoma: c‐myc, c–erb B2′ and c‐Ha‐ras , 1993, Journal of surgical oncology.

[42]  A. Harris,et al.  bcl-2 protein in non-small-cell lung carcinoma. , 1993, The New England journal of medicine.

[43]  R. Lenzi,et al.  The biology of unknown primary tumors. , 1993, Seminars in oncology.

[44]  R. Motzer,et al.  Genetic analysis in the diagnosis of neoplasms of unknown primary tumor site. , 1993, Seminars in oncology.

[45]  I. Ellis,et al.  Use of tumour marker immunoreactivity to identify primary site of metastatic cancer. , 1993, BMJ.

[46]  J. Abbruzzese,et al.  p53 gene mutation spectrum in human unknown primary tumors. , 1993, Anticancer research.

[47]  A. Szporn,et al.  ras and c-myc protein expression in colorectal carcinoma , 1992, Diseases of the colon and rectum.

[48]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[49]  E. Dmitrovsky,et al.  Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies. , 1991, Journal of the National Cancer Institute.

[50]  J. Daly,et al.  Flow cytometry and prognostic implications in patients with solid tumors. , 1990, Surgery, gynecology & obstetrics.

[51]  D. Niedzwiecki,et al.  Metastatic Adenocarcinomas of Unknown Primary Site: Prognostic Variables and Treatment Results , 1990, American journal of clinical oncology.

[52]  C. Bell,et al.  Unknown primary tumors: establishment of cell lines, identification of chromosomal abnormalities, and implications for a second type of tumor progression. , 1989, Cancer research.

[53]  T. Chevalier,et al.  Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. , 1988, Archives of internal medicine.

[54]  M. Tattersall,et al.  Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. , 1987, European journal of cancer & clinical oncology.

[55]  N. B. Atkin Chromosome 1 aberrations in cancer. , 1986, Cancer genetics and cytogenetics.

[56]  E. Cadman,et al.  An analysis of 1539 patients with cancer of unknown primary site , 1986, Cancer.

[57]  E. Casper,et al.  Adenocarcinoma of unknown primary origin: treatment with vindesine and doxorubicin. , 1985, Cancer treatment reports.

[58]  D. Hedley,et al.  Metastatic adenocarcinoma of unknown primary site: abnormalities of cellular DNA content and survival. , 1985, European journal of cancer & clinical oncology.

[59]  B. Barlogie,et al.  Flow cytometry in clinical cancer research. , 1983, Cancer research.

[60]  G. Bodey,et al.  Sequential chemotherapy for adenocarcinoma of unknown primary , 1983, American journal of clinical oncology.

[61]  S. Balcerzak,et al.  Management of patients with metastatic adenocarcinoma of unknown origin: a Southwest Oncology Group study. , 1983, Cancer treatment reports.

[62]  P. Sheedy,et al.  Computed tomography in search of cancer of unknown origin. , 1982, JAMA.

[63]  E. Levine,et al.  Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown primary site. A retrospective study. , 1982, Radiology.

[64]  M. Markman Metastatic adenocarcinoma of unknown primary site: analysis of 245 patients seen at The Johns Hopkins Hospital from 1965--1979. , 1982, Medical and pediatric oncology.

[65]  M. Tattersall,et al.  Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens. , 1980, The New England journal of medicine.

[66]  M. Tattersall,et al.  Unknown primary adenocarcinoma: incidence of overinvestigation and natural history. , 1979, British medical journal.

[67]  R. M. Wolf,et al.  Metastatic and histologic presentations in unknown primary cancer. , 1977, Seminars in oncology.

[68]  J. Yuhas,et al.  Inhibition of subcutaneously growing line 1 carcinomas due to metastatic spread. , 1974, Cancer research.

[69]  R. Hahn,et al.  Treatment of the patient with adenocarcinoma of unknown origin , 1972, Cancer.

[70]  Norman Goldstein,et al.  Metastases in carcinoma. Analysis of 1000 autopsied cases , 1950, Cancer.